{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T02:52:39Z","timestamp":1779159159614,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Public Health Experts Project","award":["G2023-2-002, G2022-2-010"],"award-info":[{"award-number":["G2023-2-002, G2022-2-010"]}]},{"name":"R&D Program of Beijing Municipal Education Commission","award":["KZ20231002545"],"award-info":[{"award-number":["KZ20231002545"]}]},{"name":"The National Key Research and Development Program of China","award":["2022YFC2305203"],"award-info":[{"award-number":["2022YFC2305203"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Many rifampicin (RIF)-resistant (RR) tuberculosis (TB) patients remain sensitive to isoniazid (INH), which challenges the strategy of using RR as an instant indicator of multiple-drug resistance tuberculosis (MDR-TB). A molecular test capable of concurrently detecting RIF and INH resistance is urgently needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The performance of a novel rapid molecular test, Innowave MTB\/RIF\/INH (InnowaveDX) was evaluated prospectively in three tertiary hospitals. Its capability of detecting resistance to RIF and INH was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In 767 pulmonary tuberculosis (PTB) patients, InnowaveDX showed significantly higher sensitivity than the Xpert MTB\/RIF assay (Cepheid, USA) (74.97% versus 68.18%; p\u2009=\u20090.003, \u03c7<jats:sup>2<\/jats:sup>\u2009=\u20098.664). This difference was particularly notable in culture-negative PTB cases (52.73% versus 41.29%; p\u2009=\u20090.001, \u03c7<jats:sup>2<\/jats:sup>\u2009=\u200910.565). Both tests demonstrated high specificity in 286 non-TB patients. The overall consistency in RIF susceptibility prediction between InnowaveDX and the Xpert assay was 97.3% (505\/519). InnowaveDX identified 83.05% (98\/118) of INH-resistant cases as predicted by phenotypic drug susceptibility testing (pDST) and 95.45% (105\/110) by another molecular method (MeltPro, Zeesan, China) for INH resistance detection on isolates. In addition, InnowaveDX showed a 99.35% consistency (154\/155) with <jats:italic>katG<\/jats:italic>, <jats:italic>inhA<\/jats:italic>, and <jats:italic>ahp<\/jats:italic>C sequencing on sputum samples. The consistency rate for MDR-TB prediction between InnowaveDX and pDST was 93.25% (332\/356). The accuracy of using RR to predict MDR-TB varied between 64.1 and 80.5%, depending on the reference method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>InnowaveDX is an easy, rapid, and sensitive molecular test for PTB diagnosis that can detect INH and RIF resistance within 3\u00a0h, facilitating MDR-TB diagnosis on the first day of hospital admission.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12941-025-00822-7","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:37:20Z","timestamp":1758883040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Innowave MTB\/RIF\/INH facilitates timely and accurate diagnosis of multiple-drug resistant tuberculosis as a near POCT technique: a multicenter prospective on-site performance evaluation study"],"prefix":"10.1186","volume":"24","author":[{"given":"Fen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongfeng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanglu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"822_CR1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2024."},{"issue":"11","key":"822_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","volume":"363","author":"CC Boehme","year":"2010","unstructured":"Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O\u2019Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005\u201315.","journal-title":"N Engl J Med"},{"key":"822_CR3","volume-title":"Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF system for the diagnosis of pulmonary and extra-pulmonary TB in adults and children. Policy update","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF system for the diagnosis of pulmonary and extra-pulmonary TB in adults and children. Policy update. Geneva: WHO; 2013."},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1128\/JCM.03395-13","volume":"52","author":"S Hu","year":"2014","unstructured":"Hu S, et al. Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis. J Clin Microbiol. 2014;52:1644\u201352.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"822_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41426-018-0114-1","volume":"7","author":"G Wang","year":"2018","unstructured":"Wang G, Dong W, Lan T, Fan J, Tang K, Li Y, Yan G, Jiang G, Ma Y, Shang Y, Qin S, Huang H. Diagnostic accuracy evaluation of the conventional and molecular tests for spinal tuberculosis in a cohort, head-to-head study. Emerg Microbes Infect. 2018;7(1):109\u201317.","journal-title":"Emerg Microbes Infect"},{"key":"822_CR6","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: Switzerland; 2019."},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"3159482","DOI":"10.1155\/2020\/3159482","volume":"2020","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhang M, Wang J, Chen S, Wu B, Zhou L, Pan A, Wang W, Wang X. Longitudinal analysis of prevalence and risk factors of rifampicin-resistant tuberculosis in Zhejiang. China Biomed Res Int. 2020;2020:3159482.","journal-title":"China Biomed Res Int"},{"issue":"4","key":"822_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jinf.2019.08.004","volume":"79","author":"Z Liu","year":"2019","unstructured":"Liu Z, Dong H, Wu B, Zhang M, Zhu Y, Pang Y, Wang X. Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: a meta-analysis of findings. J Infect. 2019;79(4):349\u201356.","journal-title":"J Infect"},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"e1003008","DOI":"10.1371\/journal.pmed.1003008","volume":"17","author":"AS Dean","year":"2020","unstructured":"Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17:e1003008.","journal-title":"PLoS Med"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"e1000146","DOI":"10.1371\/journal.pmed.1000146","volume":"6","author":"D Menzies","year":"2009","unstructured":"Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6:e1000146.","journal-title":"PLoS Med"},{"key":"822_CR11","volume-title":"Systematic screening for active tuberculosis: principles and recommendations","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013."},{"issue":"8","key":"822_CR12","doi-asserted-by":"publisher","first-page":"ofaa279","DOI":"10.1093\/ofid\/ofaa279","volume":"7","author":"F Huo","year":"2020","unstructured":"Huo F, Ma Y, Liu R, Ma L, Li S, Jiang G, Wang F, Shang Y, Dong L, Pang Y. Interpretation of discordant rifampicin susceptibility test results obtained using GeneXpert vs phenotypic drug susceptibility testing. Open Forum Infect Dis. 2020;7(8):ofaa279.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"822_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0732-8893(02)00457-1","volume":"44","author":"S Ahmad","year":"2002","unstructured":"Ahmad S, Mokaddas E, Fares E. Characterization of rpoB mutations in rifampin-resistant clinical mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis. 2002;44(3):245\u201352.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"822_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5588\/ijtld.11.0116","volume":"16","author":"FK Mukinda","year":"2012","unstructured":"Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis. 2012;16(2):196\u2013202.","journal-title":"Int J Tuberc Lung Dis"},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2334-14-18","volume":"14","author":"V Meyssonnier","year":"2014","unstructured":"Meyssonnier V, Bui TV, Veziris N, Jarlier V, Robert J. Rifampicin mono-resistant tuberculosis in France: a 2005\u20132010 retrospective cohort analysis. BMC Infect Dis. 2014;14:18.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"822_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1513\/AnnalsATS.202407-772ED","volume":"21","author":"R Perumal","year":"2024","unstructured":"Perumal R, Naidoo K. Are We Capable of Unveiling the Missed Epidemic of Isoniazid-resistant Tuberculosis? Ann Am Thorac Soc. 2024;21(10):1381\u20132.","journal-title":"Ann Am Thorac Soc"},{"key":"822_CR17","volume-title":"The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in mycobacterium tuberculosis complex: technical guide","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in mycobacterium tuberculosis complex: technical guide. Geneva: World Health Organization; 2018."},{"issue":"1","key":"822_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","volume":"18","author":"SE Dorman","year":"2018","unstructured":"Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM, study team. Xpert MTB\/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(17)30691-6.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"822_CR19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJMoa1614915","volume":"377","author":"YL Xie","year":"2017","unstructured":"Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M, Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE 3rd, Ellner JJ, Dorman SE, Alland D. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377(11):1043\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1614915.","journal-title":"N Engl J Med"},{"key":"822_CR20","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed. Geneva: World Health Organization; 2023.","edition":"2"},{"issue":"7","key":"822_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/thorax-2023-220202","volume":"79","author":"SN Danchuk","year":"2024","unstructured":"Danchuk SN, Solomon OE, Kohl TA, Dreyer V, Barilar I, Utpatel C, Niemann S, Soolingen DV, Anthony R, van Ingen J, Michael JS, Behr MA. Challenging the gold standard: the limitations of molecular assays for detection of Mycobacterium tuberculosis heteroresistance. Thorax. 2024;79(7):670\u20135. https:\/\/doi.org\/10.1136\/thorax-2023-220202.","journal-title":"Thorax"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00822-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00822-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00822-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:37:21Z","timestamp":1758883041000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-025-00822-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00822-7","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is designed and conducted in accordance with the Declaration of Helsinki, and was approved by the Ethics Committees of Beijing Chest Hospital (2023-YLQX-23). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved the manuscript and gave consent for its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}